Cabotegravir
An HIV integrase strand transfer inhibitor available in both oral and long-acting injectable forms. The injectable formulation represents a major advance, allowing HIV treatment or pre-exposure prophylaxis with once-monthly or every-two-month injections rather than daily pills. It is co-formulated or co-administered with rilpivirine for complete antiretroviral therapy.
Molekularmasse
405,4000 g/mol
LogP
2,10
TPSA
99,20 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
2D-Struktur
Cite this structure
Embed this structure
SMILES
C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12
InChI
InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1
Molecular Formula
C19H17F2N3O5
HBD / HBA
2 / 8
Rotierbare Bindungen
3
Schwere Atome
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An HIV integrase strand transfer inhibitor available in both oral and long-acting injectable forms. The injectable formulation represents a major advance, allowing HIV treatment or pre-exposure prophylaxis with once-monthly or every-two-month injections rather than daily pills. It is co-formulated or co-administered with rilpivirine for complete antiretroviral therapy.
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Yes, Cabotegravir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2403238. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54713659. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cabotegravir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cabotegravir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cabotegravir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cabotegravir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cabotegravir"></drugfyi-drug>